Merck (MRK) and ArQule (ARQL) acquisition information, including expected completion date and offer price, is displayed in the merger details table below.
This deal was successfully consummated on January 16, 2020
| Merger Details | Value |
|---|---|
| Acquisition Target Stock Name | ArQule |
| Acquisition Target Stock Ticker | ARQL |
| Acquirer Stock Name | Merck |
| Announcement Date | December 9, 2019 |
| Expected Completion Date | March 31, 2020 |
| Deal Value | $2.4bn |
| Offer Price | $20.00 |
| Payment Method | All Cash Deal, Tender Offer |
| Initial SEC Filing | 8-K |
| Investor Relations | T: 1-781-994-0300 |
| Actual Completion Date | January 16, 2020 |
The major ArQule (ARQL) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the Merck (MRK) takeover of ArQule (ARQL) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on the ArQule (ARQL) buyout, follow this link ArQule (ARQL). Change the ticker symbol as required to access news and acquisition details of additional merger stocks. The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated ARQL news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deals by simply entering a ticker symbol into the search box in the menu bar above or click on an acquisition target stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
ArQule (NASDAQ: ARQL) Merger - Acquisition News and Events
ArQule Company Profile
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company’s pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton’s tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company’s pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
